Preannouncement: EP PerMed - CARMEN2026 - Personalised Medicine for CARdiovascular, MEtabolic and kidNey diseases

The European Partnership for Personalised Medicine, EP PerMed (supported by the European Union under Horizon Europe, Grant Agreement N° 101137129), is a platform for joint programming of national and European regional research and innovation supporting activities putting into action “The Strategic Research & Innovation Agenda (SRIA) for Personalised Medicine (2023)”, SRIA for PM (2023), through dedicated research, development and innovation funding.

In this JTC2026, EP PerMed will fund research projects in human health on innovative PM strategies for patients with cardiovascular, metabolic or kidney diseases. Research projects may focus on a single disease or explore these conditions in combination. Proposals should address one or more of the following aspects:

• Innovative personalised therapeutic approaches;
• Monitoring of treatment response in patients in order to tailor treatment pathways;
• Early disease risk prediction and prevention of disease worsening or comorbidities.

The EP PerMed overall aims to:

• Encourage and enable interdisciplinary collaborations, i.e. multi-actor research, by engaging a range of relevant disciplines such as pre-clinical and clinical research, bioinformatics/health informatics/data research, ELSA research, implementation research or health economics research connected to the proposed research topic, including end-user perspective analysis to facilitate the implementation of PM;
• Encourage cross-sectorial collaborations, by including the private sector (e.g. SMEs, small and medium-sized enterprises, industry), as well as regulatory/HTA (health technology assessment) agencies and patient organisations.

More information about the eligibility criteria and rules regarding consortium composition will be available soon.